Long-term beta-blocker therapy has not been investigated in contemporary randomized clinical trials in patients with myocardial infarction and normal heart function. The aim of this study is to determine whether long-term treatment with oral beta-blockade in patients with myocardial infarction and preserved left ventricular systolic ejection fraction reduces the composite of death of any cause or new myocardial infarction..
REDUCE-SWEDEHEART is designed as a registry-based, randomized, parallel, open-label, multicenter trial. Patients, day 1-7 after myocardial infarction, who have undergone a coronary angiography and with preserved left ventricular systolic ejection fraction will be randomized to either oral beta-blockade (see "Intervention" for detailed description) at a dose according to the treating physician, or no beta-blockade. To allow quick inclusion the randomization module will be accessible by a simple web-based log-in procedure. Concomitantly, all baseline data about each individual patient will be collected from the SWEDEHEART registry. Patients will then be followed regarding all-cause mortality, myocardial infarction, heart failure, atrial fibrillation, and patient-related outcome measures (for a subgroup of patients). Patients that are eligible but not included in REDUCE-SWEDEHEART will also be followed regarding chosen treatment and the primary and secondary endpoints. Follow-up will continue until 379 primary endpoints have been observed (endpoint driven). All analyses will be performed on the intention-to-treat set, defined as all intentionally randomized patients, by randomized treatment. The primary endpoint is death or new MI. Information about death will be obtained from the Swedish population registry. Information regarding new myocardial infarction during hospitalization and readmission because of myocardial infarction or other outcome (secondary outcomes, see section below), will be obtained from the SWEDEHEART-registry (for myocardial infarction) and the patient registry of the National board of health and welfare.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
5,000
Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
Please see the section above.
Danderyd Hospital, Cardiac Intensive Care
Danderyd, Stockholm County, Sweden
Time to the composite of death of any cause or MI
Time to the composite of death of any cause or MI on an intention to treat basis (ITT)
Time frame: through study completion, an average of 3 year
All-cause death
Time to the individual component of the primary endpoint of any cause of death.
Time frame: through study completion, an average of 3 year
Myocardial infarction
Time to the individual component of the primary endpoint of MI.
Time frame: through study completion, an average of 3 year
Cardiovascular death
Time to cardiovascular death.
Time frame: through study completion, an average of 3 year
Heart failure
Time to hospital readmission due to heart failure (primary \[main\] diagnosis)
Time frame: through study completion, an average of 3 year
Atrial fibrillation
Time to hospital readmission due to atrial fibrillation (primary \[main\] diagnosis)
Time frame: through study completion, an average of 3 year
Bradycardia, Advanced AV-block, hypotension, syncope or need for pacemaker
Time to hospital readmission due to bradycardia or advanced AV-block or hypotension or syncope or need for pacemaker (primary \[main\] diagnosis)
Time frame: through study completion, an average of 3 year
Asthma or Chronic Obstructive Pulmonary Disease
Time to hospital readmission due to asthma or chronic obstructive pulmonary disease (primary \[main\] diagnosis)
Time frame: through study completion, an average of 3 year
Stroke
Time to hospital readmission due to stroke (primary \[main\] diagnosis)
Time frame: through study completion, an average of 3 year
Health related quality of life (HRQOL)
Health related quality of life (HRQOL) measured by EQ-5D in patients younger than 75 years of age
Time frame: Estimated maximal follow-up for each patient for this outcome is 1 year.
Health care costs
Health care cost analysis concerning the use beta-blocker treatment
Time frame: through study completion, an average of 3 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.